Fig. 4.

SARS-CoV-2 RNA levels from nasopharyngeal swabs by study visit. (A) The primary virologic outcome was proportion of participants with SARS-CoV-2 RNA below lower limit of quantification (LLoQ) from nasopharyngeal (NP) swabs at days 3, 7, and 14 between participants randomized to SNG001 and placebo. (B) Comparison of SARS-CoV-2 RNA levels between participants randomized to SNG001 or placebo at study entry and days 3, 7, 14, and 28, with horizontal line = median, box = interquartile range, whiskers = minimum/maximum. SARSCoV-2 RNA was measured using a quantitative Abbott m2000sp/rt platform with a limit of detection (LOD) of 1.4 log₁₀ copies/mL, lower limit of quantification (LLoQ) of 2 log₁₀ copies/mL, and upper limit of quantification (ULoQ) of initially 7, then 8 log₁₀ copies/mL.